Freeman Health System - Freeman West | |
1102 West 32nd Street, Joplin, Missouri 64804 | |
(417) 347-1111 | |
Name | Freeman Health System - Freeman West |
---|---|
Type | Acute Care Hospital |
Location | 1102 West 32nd Street, Joplin, Missouri |
Ownership | Voluntary non-profit - Private |
Emergency Services | Yes |
Medicare ID (CCN) | 260137 |
NPI Number | 1265546048 |
Organization Name | FREEMAN-OAK HILL HEALTH SYSTEM |
Doing Business As | FREEMAN HEALTH SYSTEM |
Address | 1102 W 32nd St, Joplin, MO 64804 |
Hospital Type | General Acute Care Hospital |
Phone Number | 417-347-1111 |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Company's MEDIHONEY Calcium Alginate Dressing.
Midday naps are associated with reduced blood pressure levels and prescription of fewer antihypertensive medications, according to research presented at ESC Congress today by Dr Manolis Kallistratos, a cardiologist at Asklepieion Voula General Hospital in Athens, Greece.
OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.
Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.
› Verified 9 days ago
NPI Number | 1780747097 |
Organization Name | FREEMAN-OAK HILL HEALTH SYSTEM |
Address | 1102 West 32nd Street, Joplin, MO 64804 |
Hospital Type | General Acute Care Hospital |
Phone Number | 417-347-5833 |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Company's MEDIHONEY Calcium Alginate Dressing.
Midday naps are associated with reduced blood pressure levels and prescription of fewer antihypertensive medications, according to research presented at ESC Congress today by Dr Manolis Kallistratos, a cardiologist at Asklepieion Voula General Hospital in Athens, Greece.
OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.
Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.
› Verified 9 days ago
NPI Number | 1891809679 |
Organization Name | FREEMAN-OAK HILL HEALTH SYSTEM |
Doing Business As | FREEMAN HEALTH SYSTEM |
Address | 1102 W 32nd St, Joplin, MO 64804 |
Hospital Type | General Acute Care Hospital |
Phone Number | 417-347-1111 |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Company's MEDIHONEY Calcium Alginate Dressing.
Midday naps are associated with reduced blood pressure levels and prescription of fewer antihypertensive medications, according to research presented at ESC Congress today by Dr Manolis Kallistratos, a cardiologist at Asklepieion Voula General Hospital in Athens, Greece.
OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.
Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.
› Verified 9 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Company's MEDIHONEY Calcium Alginate Dressing.
Midday naps are associated with reduced blood pressure levels and prescription of fewer antihypertensive medications, according to research presented at ESC Congress today by Dr Manolis Kallistratos, a cardiologist at Asklepieion Voula General Hospital in Athens, Greece.
OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.
Many breast cancer patients are treated with a drug called tamoxifen. The substance blocks the effect of estrogen and thus suppresses the growth signals of this hormone in cancer cells. When resistance to the drug develops, tumor cells change their growth program: They change their behavior and shape, become more mobile and also adopt the ability to invade surrounding tissue. Scientists working with PD (Associate Professor) Dr. Stefan Wiemann of the German Cancer Research Center (DKFZ) have now also observed these changes in tamoxifen resistant breast cancer cells.
› Verified 9 days ago
Mercy Hospital Joplin Acute Care Hospital Location: 100 Mercy Way, Joplin, Missouri 64804 Phone: (417) 781-2727 | |
Freeman Health System - Freeman West Acute Care Hospital Location: 1102 West 32nd Street, Joplin, Missouri 64804 Phone: (417) 347-1111 |